CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »
In May 2018, Aimovig (erenumab) became the first CGRP monoclonal antibody to be approved for the prevention of migraine in adults. Approval was supported by data including results of the Phase 3 STRIVE and ARISE studies in episodic migraine and the results of a large Phase 2 study in chronic migraine. Erenumab was further investigated in the Phase 3b LIBERTY study of patients with migraine who had failed on 2-4 previous preventive therapies.
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
